aan

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual MeetingAnnexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

April 08, 2025 16:05 ET  | Source: Annexon Biosciences Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable…

3 weeks ago
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

April 04, 2025 08:30 ET  | Source: Xenon Pharmaceuticals Inc. Three epilepsy posters to be presented in scientific sessions at…

4 weeks ago